UCB and Dermira announce U.S. and EU regulatory submissions for CIMZIA®
UCB and Dermira announced the UCB submission of a sBLA to the FDA for CIMZIA® (certolizumab pegol). Separately, UCB also submitted a regulatory filing with the EMA. Both regulatory filings seek to expand the approved indications for CIMZIA to include moderate-to-severe chronic plaque psoriasis. July 25, 2017